34.42
price up icon1.47%   0.50
after-market Handel nachbörslich: 34.59 0.17 +0.49%
loading
Schlusskurs vom Vortag:
$33.92
Offen:
$35
24-Stunden-Volumen:
4.38M
Relative Volume:
0.68
Marktkapitalisierung:
$3.87B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-37.01
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
+2.64%
1M Leistung:
+29.25%
6M Leistung:
+34.14%
1J Leistung:
-52.99%
1-Tages-Spanne:
Value
$33.00
$35.25
1-Wochen-Bereich:
Value
$30.85
$36.11
52-Wochen-Spanne:
Value
$18.92
$81.73

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name
Firmenname
Viking Therapeutics Inc
Name
Telefon
858-704-4660
Name
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Name
Mitarbeiter
51
Name
Twitter
@viking_vktx
Name
Nächster Verdiensttermin
2025-10-22
Name
Neueste SEC-Einreichungen
Name
VKTX's Discussions on Twitter

Vergleichen Sie VKTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VKTX
Viking Therapeutics Inc
34.42 3.83B 0 -99.15M -74.25M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.39 108.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.43 60.82B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.95 61.02B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
817.32 50.01B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.81 34.05B 4.56B -176.77M 225.30M -1.7177

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2025-04-08 Eingeleitet Goldman Neutral
2025-02-13 Eingeleitet Scotiabank Sector Outperform
2025-02-07 Eingeleitet Citigroup Neutral
2024-12-02 Eingeleitet Piper Sandler Overweight
2024-11-22 Eingeleitet B. Riley Securities Buy
2024-11-04 Bestätigt H.C. Wainwright Buy
2024-09-11 Eingeleitet JP Morgan Overweight
2024-06-27 Eingeleitet Morgan Stanley Overweight
2024-05-16 Hochstufung Raymond James Outperform → Strong Buy
2024-03-26 Bestätigt Oppenheimer Outperform
2024-03-07 Eingeleitet Jefferies Buy
2024-02-28 Bestätigt Oppenheimer Outperform
2023-05-31 Fortgesetzt ROTH MKM Buy
2023-03-28 Bestätigt Maxim Group Buy
2023-03-17 Eingeleitet Stifel Buy
2021-07-29 Fortgesetzt BTIG Research Buy
2021-05-25 Herabstufung Raymond James Strong Buy → Outperform
2020-06-05 Eingeleitet BMO Capital Markets Outperform
2020-05-05 Eingeleitet Chardan Capital Markets Buy
2020-05-01 Eingeleitet BTIG Research Buy
2019-07-16 Eingeleitet Oppenheimer Outperform
2019-06-25 Eingeleitet Stifel Buy
2019-03-29 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-03-14 Bestätigt Maxim Group Buy
2019-02-22 Eingeleitet SVB Leerink Mkt Perform
2018-12-12 Eingeleitet B. Riley FBR Buy
2018-11-19 Hochstufung Raymond James Outperform → Strong Buy
2018-09-18 Bestätigt H.C. Wainwright Buy
2018-09-18 Bestätigt Maxim Group Buy
2018-09-18 Bestätigt Raymond James Outperform
2018-07-20 Eingeleitet SunTrust Buy
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-01 Bestätigt Laidlaw Buy
2018-05-31 Bestätigt Maxim Group Buy
2018-03-26 Fortgesetzt H.C. Wainwright Buy
2017-11-28 Bestätigt Maxim Group Buy
2017-11-21 Eingeleitet ROTH Capital Buy
Alle ansehen

Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten

pulisher
Oct 25, 2025

Heatmap analysis for Viking Therapeutics Inc. and competitorsEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

How hedge fund analytics apply to Viking Therapeutics Inc. stockWeekly Market Report & High Yield Stock Recommendations - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Live market analysis of Viking Therapeutics Inc.2025 Dividend Review & Technical Entry and Exit Alerts - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

What makes Viking Therapeutics Inc. stock attractive to growth fundsTrade Risk Assessment & Proven Capital Preservation Methods - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Can trapped investors hope for a rebound in Viking Therapeutics Inc.2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Can Viking Therapeutics Inc. stock hit record highs again2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst - The Globe and Mail

Oct 25, 2025
pulisher
Oct 25, 2025

Can Viking Therapeutics Inc. (1VT) stock sustain margin levelsJuly 2025 Volume & Stepwise Swing Trade Plans - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? - MSN

Oct 25, 2025
pulisher
Oct 25, 2025

Is Viking Therapeutics Inc. forming a bottoming baseWeekly Risk Report & Entry and Exit Point Strategies - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Why Viking Therapeutics Inc. stock attracts high net worth investorsEarnings Summary Report & Daily Oversold Stock Bounce Ideas - newser.com

Oct 25, 2025
pulisher
Oct 24, 2025

Leerink Partners Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $118 - 富途牛牛

Oct 24, 2025
pulisher
Oct 24, 2025

JP Morgan Lowers Price Target for Viking Therapeutics (VKTX) to $75 | VKTX Stock News - GuruFocus

Oct 24, 2025
pulisher
Oct 24, 2025

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2025 Earnings Call Transcript - Insider Monkey

Oct 24, 2025
pulisher
Oct 24, 2025

Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus

Oct 24, 2025
pulisher
Oct 24, 2025

Viking Therapeutics Navigates Regulatory Risks Amid U.S. Policy Shifts - TipRanks

Oct 24, 2025
pulisher
Oct 24, 2025

Viking Therapeutics (VKTX): Assessing Valuation After 36% Monthly Share Price Gain - simplywall.st

Oct 24, 2025
pulisher
Oct 23, 2025

Viking Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges - TipRanks

Oct 23, 2025
pulisher
Oct 23, 2025

Viking Bolts Higher; It's Moving At 'Lightning' Speed - Investor's Business Daily

Oct 23, 2025
pulisher
Oct 23, 2025

Noteworthy Thursday Option Activity: VKTX, KODK, GEO - Nasdaq

Oct 23, 2025
pulisher
Oct 23, 2025

Here's Why This Obesity Drug Company's Share Price Soared Today - AOL.com

Oct 23, 2025
pulisher
Oct 23, 2025

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

Healthcare Stocks Show Mixed Moves As Companies Shift Strategies - Finimize

Oct 23, 2025
pulisher
Oct 23, 2025

Why Is Viking Therapeutics Stock Rising Today? - Benzinga

Oct 23, 2025
pulisher
Oct 23, 2025

Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside - Stocktwits

Oct 23, 2025
pulisher
Oct 23, 2025

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith) (VKTX) - Seeking Alpha

Oct 23, 2025
pulisher
Oct 23, 2025

MASH, Metsera Deals Send Analysts Marauding to Viking - BioSpace

Oct 23, 2025
pulisher
Oct 23, 2025

Viking Therapeutics: The Prime Target In The Obesity Gold Rush (NASDAQ:VKTX) - Seeking Alpha

Oct 23, 2025
pulisher
Oct 23, 2025

Viking Therapeutics stock price target raised by Cantor Fitzgerald on positive outlook - Investing.com

Oct 23, 2025
pulisher
Oct 23, 2025

Viking Therapeutics (VKTX) Receives Updated Price Target from Mo - GuruFocus

Oct 23, 2025

Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$37.26
price up icon 1.11%
$91.28
price up icon 2.21%
$29.89
price up icon 0.07%
$105.66
price up icon 0.87%
$159.66
price down icon 0.29%
biotechnology ONC
$310.81
price up icon 0.25%
Kapitalisierung:     |  Volumen (24h):